secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2025-11-24T23:59:59+00:00
Accession:  0001193125-25-292015
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa Pharma enters into $250M ATM equity offering facility with Leerink Partners
--------------------------------------------------------------------------------

- Up to $250M of American Depositary Shares may be sold through Leerink as sales agent.
- Commission of 3.0% on gross proceeds; Leerink also receives up to $150K legal expense reimbursement.
- No minimum offering amount; net proceeds expected for working capital, capex, and general corporate purposes.
- Amends and restates prior sales agreement dated January 27, 2023, with Leerink.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000119312525292015/0001193125-25-292015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000119312525292015/d23843d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-292015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer